InVivo NSA has acquired AdGène
July 2015 — InVivo NSA has acquired AdGène for US$8 million.
InVivo NSA, along with its subsidiaries, engages in complete feed, premix, additives, analysis laboratories, and animal health businesses in Central America, South America, France/EMEA, and Asia. InVivo Labs, the analytical division of InVivo NSA, and AdGène, an expert laboratory in molecular biology in France, have announced their strategic union. This transaction allows InVivo Labs to reinforce its analytical portfolio related to food safety and traceability. Moreover, it positions the new group as a significant player in the high potential growing market of bioanalysis.
Founded in 2001, AdGène is a French laboratory that specializes in molecular biology, genetic analyses and water quality control. The laboratory employs 20 people and has high-tech equipment.
Our role in the transaction
Oaklins' team in France advised the buyer in this transaction.
Talk to the deal team
Related deals
Cibus has acquired Aweta from Standard Investment
Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreTandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.
Learn more